Invention Grant
- Patent Title: Sialylated fetuin-A as a marker of immunotherapy efficacy
-
Application No.: US15528250Application Date: 2015-11-23
-
Publication No.: US10884002B2Publication Date: 2021-01-05
- Inventor: Vincent Lombardi , Noémie Caillot , Emmanuel Nony , Philippe Moingeon , Véronique Bodo , Julien Bouley
- Applicant: STALLERGENES
- Applicant Address: FR Antony
- Assignee: STALLERGENES
- Current Assignee: STALLERGENES
- Current Assignee Address: FR Antony
- Agency: Browdy and Neimark, PLLC
- Priority: EP14306857 20141121
- International Application: PCT/EP2015/077360 WO 20151123
- International Announcement: WO2016/079339 WO 20160526
- Main IPC: G01N33/68
- IPC: G01N33/68 ; C07K14/47 ; G01N33/74 ; A61K39/35 ; C07K16/18 ; A61K39/00 ; C12N15/115
Abstract:
The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
Public/Granted literature
- US20170370946A1 SIALYLATED FETUIN-A AS A MARKER OF IMMUNOTHERAPY EFFICACY Public/Granted day:2017-12-28
Information query
IPC分类:
